Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Remdesivir and its antiviral activity against COVID-19: A systematic review

Andri Frediansyah, Firzan Nainu, Kuldeep Dhama, Mudatsir Mudatsir, Harapan Harapan

1. Introduction

The current coronavirus disease 2019 (COVID-19) pandemic, has caused considerable challenges to the national healthcare systems of most affected countries.1,2 The most common clinical manifestations of COVID-19 include fever, cough, dyspnea, chest pain, and pneumonia with ground-glass opacities being the most common finding in computed tomography imaging.3,4 Aside from respiratory symptoms, COVID-19 could involve cardiac manifestations,5 the digestive system,6 and other organs.7–9 The progression and severity of COVID-19 may be associated with dysregulation of host immune responses.10 As on June 8, 2020, over 7 million confirmed COVID-19 cases and 400,000 deaths were reported, according to the COVID-19 Global Cases database.11 The rapid transmission of the virus is mainly owing to its high reproductive number (R0), with a mean of 3.28,12 implying that one infected person could transmit the virus to up to three unvaccinated individuals. The virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a member of the family Coronaviridae and genus Betacoronavirus, together with SARS-CoV and Middle East respiratory syndrome-related coronavirus (MERS-CoV).8 The virus has 79.6% sequence similarity with SARS-CoV.13 A specific antiviral treatment for COVID-19 is yet to be identified;14 therefore, several strategies have been proposed to treat patients, including the use of convalescent plasma and interferon (IFN), as well as interleukin 6 receptor inhibitors since they have the potential to inhibit the cytokine storm.15 Chloroquine and hydroxychloroquine that inhibit endocytosis-mediated viral entry, inhibit endosomal acidification, and disrupt glycosylation of angiotensin converting enzyme 2 (ACE2),16–18 as well as ivermectin that inhibits nuclear transport of viral proteins,19,20 have been used to treat COVID-19. In addition, antivirals that inhibit protease inhibitors21–25 and nucleotide or nucleoside analogs that inhibit viral RNA synthesis17,26–28 have been repurposed for the
treatment of the SARS-CoV-2 infection. Nucleoside analogs represent a group of drugs that inhibit reverse transcription and are among the most potent antiviral agents available to combat the SARS-CoV-2 infection—within this group is remdesivir. The objective of this review was to summarize evidence from in vitro studies, in vivo studies, use in patients with COVID-19 under emergency protocol, and clinical trials to provide comprehensive information on the potential of remdesivir in the treatment of patients with COVID-19.

2. Materials and methods

Relevant articles were searched on PubMed and Google Scholar using the search terms “remdesivir”, AND “coronavirus”, OR “SARS-CoV”, OR “MERS-CoV”, OR “SARS-CoV-2” in the title and abstract. Recent clinical trials assessing the efficacy of remdesivir against COVID-19 were also searched on the ClinicalTrials.gov database. The screened publications were classified and analyzed based on the study types: in vitro, in vivo, use in patients.

Fig. 1. Structure and mechanism of action of remdesivir (GS-5734) and its pharmacological active form (GS-441524).
vitro, in vivo, emergency use in hospitals, and clinical trials. All available articles until May 4, 2020 were considerate eligible.

3. Results

The search combinations yielded 21 main references related to remdesivir. Antiviral activity and mechanism of remdesivir in both non- and coronaviruses have been reported in several in vitro studies. 17,19-29 In vivo studies have been conducted to assess antiviral effect of remdesivir on non-coronaviruses using rhesus monkeys 40 and African green monkeys 40,41 as well as on coronavirus such as in mice 42,43 and rhesus macaques. 44,45 The antiviral effect of remdesivir also have been assessed in humans 46 and it have been used to treat severe COVID-19 patients, as an emergency use. 47,48 Although only one clinical trial has been conducted to assess the effectiveness and safety of remdesivir for COVID-19, 49 several clinical trials are ongoing in some countries.

4. Discussion

4.1. Remdesivir: an introduction

Remdesivir (GS-5734; Gilead Sciences Inc., US) is an investigational nucleoside analog that acts as a competitive inhibitor of viral RNA-dependent RNA polymerase (RdRp) (Fig. 1). 13 It is a prodrug with a molecular formula of C$_{23}$H$_{35}$N$_{6}$O$_{6}$P and an exact mass of 602.23 Da. In the body, remdesivir is transformed into an active molecule known as GS-441524 MERS-CoV HAE IC$_{50}$ = 0.074 μM. 24 The viral load was fit in a logarithmic scale (log$_{10}$ TCID$_{50}$/mL) under increasing concentrations of remdesivir or GS-441524.

The RdRp sequences of SARS-CoV-2 and SARS-CoV display more than 80% similarity. 50,59 Therefore, it was suggested that remdesivir could potentially exert antiviral activities against SAR-CoV-2. Remdesivir was found to have an EC$_{50}$ of 0.77 against SARS-CoV-2 in Vero E6 cells (Table 1). 17 This activity of remdesivir was higher than that of the other drugs used in the study, such as ribavirin, penciclovir, favipiravir, nafamostat, nitosoxanide, and chloroquine, which showed EC$_{50}$ values of 109.5, 95.96, 61.88, 22.50, 2.12, and 1.13 μM, respectively. 17 Another study in Vero E6 cells also revealed that remdesivir inhibited the replication of SARS-CoV-2, with an EC$_{50}$ of 23.15 μM, showing the strongest antiviral activity among the tested drugs. 59 In this study, the viral load was fit in a logarithmic scale under increasing remdesivir concentrations, rather than a linear scale reported previously. 17 These initial studies suggest that remdesivir inhibits the replication of SARS-CoV-2 and has the potential to be used in the treatment of COVID-19.

4.2. Evidence from in vitro studies

In 2015, a study showed that remdesivir is an effective inhibitor of the Ebola virus. 20 Its half-maximal effective concentration (EC$_{50}$), the drug concentration that induces a response halfway between the baseline and maximum after a specified exposure time, varied between 0.07 and 0.14 μM in Ebola-infected cells such as HeLa, HFF-1, HMVEC-TERT, and Huh-7. 30 Studies on the inhibitory effects of remdesivir against various viruses have been conducted using seven virus families, namely, filo-, paramyx-, pneumo-, bunya-, arena-, rhabo-, and flaviviruses. 30,44 Another study showed that phosphorylated GS-441524, the active molecule of remdesivir, inhibited feline infectious peritonitis in CRFK cells, with a half maximal inhibitory concentration (IC$_{50}$) of the drug concentration at which half of the peak inhibiting effect of the drug against a specific viral function is achieved) of 0.78 μM. 51 The EC$_{50}$ of remdesivir against the murine hepatitis virus is 0.03 μM. 13 Remdesivir also exerts antiviral activities against MERS-CoV, Junin virus, and Lassa fever virus in HeLa cells, with EC$_{50}$ values of 0.34, 0.47, and 1.48 μM, respectively. 30 Another study revealed that remdesivir inhibits SARS-CoV and MERS-CoV in human airway epithelial (HAE) cells, with EC$_{50}$ values of 0.069 and 0.074 μM, respectively. 44 The summary of the EC$_{50}$ and IC$_{50}$ of remdesivir and its active component GS-441524 against highly pathogenic human coronaviruses (MERS-CoV and SARS-CoV) is presented in Table 1.

Remdesivir inhibits RdRp; its antiviral activity against RdRp has been reported in Huh7 human cells infected with CoV-OC43, CoV-229E, and PDCoV, with EC$_{50}$ values ranging between 0.02 and 0.17 μM. 35 The same mechanism, i.e., the inhibition of RdRp, has also been reported in Ebola virus. 36,37 A recent study revealed that the inhibitory mechanism of the active triphosphate molecule of remdesivir against MERS-CoV in insect cells involved various nonstructural proteins (nsp), such as nsp5, nsp7, nsp8, and nsp12 (RdRp). 38

| Component | Virus | Cell line | EC$_{50}$ or IC$_{50}$ | Reference |
|-----------|-------|-----------|------------------------|-----------|
| Remdesivir | MERS-CoV | Calu-3 2B4 | EC$_{50}$ = 0.025 μM | 24 |
|           | HAE   |           | IC$_{50}$ = 0.074 μM  | 24 |
|           | Calu-3 2B4 | IC$_{50}$ = 0.074 μM | 41 |
|           | HAE   |           | EC$_{50}$ = 0.07 μM   | 41 |
| SARS-CoV  | HAE   |           | EC$_{50}$ = 0.069 μM  | 34 |
| SARS-CoV-2 | Vero E6 | EC$_{50}$ = 0.77 μM | 17 |
| GS-441524 | MERS-CoV | HAE | EC$_{50}$ = 0.86 μM | 33 |
|           | SARS-CoV | HAE | EC$_{50}$ = 0.18 μM | 33 |

Calu-3: human bronchial epithelial cells; HAE: human airway epithelial cells; MERS-CoV: Middle East respiratory syndrome-related coronavirus; SARS-CoV-2: The virus, severe acute respiratory syndrome coronavirus 2; SARS-CoV: severe acute respiratory syndrome-related coronavirus; Vero E6: African green monkey kidney epithelial cells.

a The viral load was fit in a linear scale (the percentage of inhibition) under increasing concentrations of remdesivir or GS-441524.

b The viral load was fit in a logarithmic scale (log$_{10}$ TCID$_{50}$/mL and log$_{10}$ viral RNA copies/mL) under increasing concentrations of remdesivir.

4.3. Evidence from in vivo studies

In 2016, an in vivo study was conducted using Ebola-infected rhesus monkeys (a non-human primate) and various doses of remdesivir intramuscular injections. 30 Post-exposure revealed that remdesivir exerted protective effects by inhibiting viral replication. 30 The concentration of form of remdesivir, was 10 μM in peripheral blood mononuclear cells after administration of 10 mg/kg remdesivir. 30 A study in Nipah virus-infected African green monkeys showed the protective effects of remdesivir: half of the remdesivir-treated monkeys (n = 4) developed mild respiratory symptoms and the other half recovered; those in the control group developed severe respiratory disease. 49

Remdesivir has also been shown to exert antiviral activity against coronaviruses. Remdesivir treatment was found to reduce the viral load in MERS-CoV-infected Ces1c$^{-/-}$ hDPP4 mice and was phenotypically associated with improved pulmonary function and decreased likelihood of acute lung injury development in infected animals. 35 In addition, remdesivir inhibited MERS-CoV replication in the pulmonary organs of rhesus macaques and led to a reduction in lung lesions. 40 Remdesivir also reduced the viral load in the lung and improved the respiratory function of SARS-CoV MA15-infected mice. 42 A recent study showed that remdesivir administration to SARS-CoV-2-infected rhesus macaques improved pulmonary lesions, according to radiographs; reduced viral titers in bronchoalveolar lavage after 12 h of treatment; and reduced the viral load in the lungs after 7 days of treatment. Moreover, the remdesivir-treated animals did not show any signs of pulmonary disease. 43
4.4. Results from patients with COVID-19 and clinical trials

Historically, remdesivir was tested to treat patients with Ebola in a randomized clinical trial in the Democratic Republic of the Congo in 2018.\(^4\) In 2020, remdesivir was included in the “Solidarity” international clinical trial conducted by the World Health Organization in an attempt to find an effective treatment for COVID-19.\(^5\) As a timely response to the pandemic, patients with COVID-19 have been treated with remdesivir in emergency protocols. In the first patient with COVID-19 treated with remdesivir, a 35-year-old from Washington, pneumonia improved after 7 days of treatment.\(^6\) In Seattle, USA, remdesivir was used as a compassionate drug to treat seven critically ill patients.\(^6\) A larger study found that, following a 10-day course of remdesivir treatment (intravenous administration at 200 mg on day 1, followed by 100 mg daily), 68% (36 of 53) of patients with COVID-19 showed clinical improvement; however, there was no control group in this study.\(^7\) Therefore, this information is insufficient to confirm the efficacy of remdesivir in treating patients with COVID-19.

To adequately assess the efficacy of remdesivir, clinical trials are ongoing in countries such as USA, Norway, Canada, France, and China. A list of currently ongoing clinical trials has been presented in Table 2. Although the length of treatment differs slightly, the dose of remdesivir is similar: 200 mg on day 1, followed by 100 mg for the rest of the treatment period.

The first randomized, double-blind, placebo-controlled, multicenter clinical trial was reported on April 29, 2020.\(^8\) The study was conducted in China with 237 patients (158 in the remdesivir group and 79 in the placebo control group), and the primary endpoint was the time taken to achieve clinical improvement. The study revealed that treatment with remdesivir did not lead to a significant reduction in the time taken to achieve clinical improvement. In addition, mortality and viral clearance time in patients with severe COVID-19 were not significantly different from those in the placebo group, suggesting that remdesivir had poor clinical benefits. This further suggests that in COVID-19, viral propagation is not the main factor responsible for disease severity. On this account, the antiviral properties of remdesivir will not be beneficial. The severity of COVID-19 has been associated with the cytokine release storm,\(^9\) suggesting that host immune responses play an important role in this event. Therefore, a combination of remdesivir with immunosuppressants (for example sarilumab, an IL-6 the inhibitor) and/or other antiviral agents might potentiate the antiviral activity of remdesivir and mitigate the immunopathological injury caused by excessive immune effectors.\(^10\)

Nonetheless, during the same trial,\(^8\) in remdesivir-treated patients with COVID-19, especially those treated within 10 days of symptom onset, faster clinical improvement was observed than that in the placebo group. Unfortunately, the study was terminated prematurely owing to the occurrence of more frequent adverse events in the remdesivir group than in the placebo group.\(^11\) Considering these findings, the small sample size, and because the study was unexpectedly terminated, it may be insufficient to elucidate the efficacy of remdesivir.\(^11\) Furthermore, the pharmacokinetics of remdesivir and its active metabolite in the respiratory tracts and/or other infected organs remain largely unknown in patients with COVID-19.\(^12\) Therefore, the results of ongoing clinical trials (Table 1) are warranted to provide conclusive evidence regarding the efficacy of remdesivir in patients with COVID-19.

The pharmacokinetic profile of remdesivir, particularly the concentrations of the active metabolite, GS-441524, in the respiratory tract or other infected tissues in patients with severe COVID-19 are unknown.\(^13\) In addition, currently available data on remdesivir are lacking, in particular those in drug-drug, drug-gene, and drug-disease interactions. This information is important in predicting possible negative outcomes that may arise during treatment.

Table 2

| Identifier number | Title                                                                 | Expected participants | Length of treatment | Location       |
|-------------------|----------------------------------------------------------------------|-----------------------|---------------------|----------------|
| NCT04292899       | Study to evaluate the safety and antiviral activity of remdesivir     | 6000                  | 5–10 days           | USA            |
|                   | (GS-5734^4\(^4\)) in participants                                       |                       | (and possibly extension) |
| NCT04292730       | Study to evaluate the safety and antiviral activity of remdesivir     | 1600                  | 5–10 days           | USA            |
|                   | (GS-5734^4\(^4\)) in participants with moderate                               |                       | (and possibly extension) |
|                   | coronavirus disease (COVID-19) compared to standard of care treatment  |                       |                     |
| NCT04321616       | The efficacy of different antiviral drugs in COVID-19 infected patients | 700                   | 10 days             | Norway         |
| NCT04330690       | Treatments for COVID-19: Canadian Arm of the Solidarity Trial (CATCO) | 440                   | 9 days              | Canada         |
| NCT04280705       | Adaptive COVID-19 treatment Trial (ACTT)                                | 800                   | 10 days             | USA            |
| NCT04315948       | Trial of treatments for COVID-19 in hospitalized adults (DiCoVrby)      | 3100                  | 10 days             | France         |
| NCT04349410       | The Fleming (FMTVDM) directed CoVid-19 treatment protocol              | 500                   | 10 days             | USA            |
| NCT04365725       | Multicenter, retrospective study of the effects of remdesivir in the treatment of severe covid-19 infections (REMDECO-19) | 200                   | 15 days             | France         |

5. Conclusion

Remdesivir is a nucleotide analog produg that inhibits SARS-CoV-2 RdRp. Its viral activities against SARS-CoV-2 have been shown in both in vitro and in vivo studies. Remdesivir has been used in several countries as an emergency drug for patients with COVID-19, and some patients showed improved clinical outcomes. However, large-scale clinical trials should be conducted to confirm the efficacy of remdesivir in treating patients with COVID-19.

Authors’ contributions

AF and HH conceived and designed the study. AF, FN, and HH were responsible for data collection. AF and HH wrote the initial manuscript. KD, MM, and HH critically revised the manuscript. All authors have read the final manuscript.

Declaration of competing interest

The authors declare that they have no competing interests.
